Pulmatrix Supply Chain
Supply Chain of Pulmatrix (PULM) as of Oct 18, 2026.
Get this data via API
Financial Data API
Supply Chain
-
Last updated:
Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.
Pulmatrix Supply Chain
Correlation: how closely stock prices move together
Same directionNo relationOpposite
2 companies
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Cipla | -0.45 | -0.22 | -0.71 | |
| 2 | -0.67 | -0.41 | -0.63 |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pulmatrix Stock analysis
What does Pulmatrix do? Pulmatrix Inc is a clinical stage biotechnology company based in Lexington, Massachusetts, focused on developing inhaled therapeutic products for respiratory and other diseases. The company went public via an IPO on March 21, 2014, and currently employs two full-time staff members. Pulmatrix utilizes its proprietary dry powder delivery technology, iSPERSE, to create inhaled therapies designed for local or systemic drug delivery to the lungs. The iSPERSE platform enables the formulation of small or large molecule drugs into dry powder form, engineered to be small, dense particles with optimal dispersibility and airway delivery. This technology is compatible with various dry powder inhaler devices and supports a wide range of drug substances, including small molecules and biologics. Pulmatrix has several therapeutic candidates in development, including Pulmazole, PUR1800, PUR5700, PUR3000, and PUR4000. The company's website is www.pulmatrix.com. Pulmatrix operates within the pharmaceuticals sector of the health care industry, targeting serious respiratory conditions through innovative inhaled drug delivery solutions. Pulmatrix is one of the most popular companies on Eulerpool.
All Key Metrics — Pulmatrix
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth